Čes. slov. farm. 2005, 54(3):137-140
Solubilization and Complexation of the Antileukotrienic Drug Quinlukast in Aqueous Solutions of Cyclodextrins
- 1 Farmaceutická fakulta Univerzity Komenského v Bratislave, Katedra fyzikálnej chémie liečiv
- 2 Farmaceutická fakulta Univerzity Komenského v Bratislave, Katedra farmaceutickej analýzy a nukleárnej farmácie
Solubility of the new antileukotrienic drug quinlukast (4-{[4-(2-quinolylmethoxy)phenyl]sulfanyl}benzoic acid) was determined in water and in aqueous solutions of α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD, average degree of substitution 0.8), and methyl-β-cyclodextrin (M-β-CD, average degree of substitution 1.8). The determined solubility of quinlukast in water was 0.081±0.008 mmol/l (3.12± 0.30 mg/100ml) and only an insignificant increase in quinlukast solubility was observed in aqueous solutions of β-CD. However, three well soluble cyclodextrins showed a marked solubilizing effect, in aqueous solutions with a moderate cyclodextrin concentration 5 g/100ml, a 12-fold increase in quinlukast solubility was observed in the case of M-β-CD, and a 10-fold increase in the case of both HP-β-CD and α-CD. Phase solubility diagrams of quinlukast in aqueous solutions of these cyclodextrins (up to 0.05 mol/l) were determined. In the cases of M-β-CD and HP-β-CD, the solubility diagrams were linear (AL) and they corresponded to the formation of a soluble inclusion complex quinlukast - cyclodextrin 1:1 with the evaluated stability constants K11 300±35 l/mol and 260±30 l/mol for M-β-CD and HP-β-CD, respectively. The phase solubility diagram of quinlukast in aqueous solutions of α-CD showed a marked positive deviation (AP) from linearity, the solubilization efficiency of dilute α-CD solutions was relatively low but it increased progressively with the increasing α-CD concentration. In the overall evaluation, the cyclodextrins α-CD, HP-β-CD and M-β-CD appeared to be suitable for the quinlukast solubilization into aqueous solutions.
Keywords: quinlukast; antileukotrienic drug; solubility; solubilization; cyclodextrins; inclusion complexes
Received: October 11, 2004; Accepted: November 25, 2004; Published: March 1, 2005 Show citation
References
- Kuchař, M., Kmoníček, V., Panajotová, V. et al.: U.S. 6,303,612 B1, 2001; Chem. Abstr., 2000; 132, 49797.
- Kuchař, M., Kmoníček, V., Panajotová, V. et al.: Collect. Czech. Chem. Commun., 2004; 69, 2098-2120.
Go to original source...
- Kuchař, M., Čulíková, K., Panajotová, V. et al.: Collect. Czech. Chem. Commun., 1998; 63, 103-114.
Go to original source...
- Wsól, V., Szotáková, B., Baliharová, V. et al.: Collect. Czech. Chem. Commun., 2004; 69, 689-702.
Go to original source...
- Hörter, D., Dressman, J. B.: Adv. Drug Delivery Rev., 2001; 46, 75-87.
Go to original source...
Go to PubMed...
- Thompson, D. O.: Crit. Rev. Ther. Drug. Carr. Syst., 1997; 14, 1-104.
Go to original source...
- Zhang, M.-Q., Rees, D. C.: Exp. Opin. Ther. Patents, 1999; 9, 1697-1717.
Go to original source...
- Loftsson, T., Magnúsdóttir, A., Másson, M., Sigurjónsdóttir, J. F.: J. Pharm. Sci., 2002; 91, 2307-2316.
Go to original source...
Go to PubMed...
- Kopecký, F., Kopecká, B., Kaclík, P.: Čes. slov. Farm., 2003; 52, 33-38.
- Kopecký, F., Kopecká, B., Kaclík, P.: J. Inclusion Phenom. Macrocycl. Chem., 2001; 39, 215-217.
Go to original source...
- Kopecký, F., Kopecká, B., Kaclík, P.: Čes. slov. Farm., 1999; 48, 287-290.
- MacKenzie, C. R., Fawcet, J. P., Boulton, D. W., Tucker, I. G.: Int. J. Pharm., 1997; 159, 191-196.
Go to original source...
- Kamphorst, A. O., Mendes de Sá, I., Faria, A. M. C., Sinisterra, R. D.: Eur. J. Pharm. Biopharm., 2004; 57, 199-205.
Go to original source...
Go to PubMed...
- Kopecký, F., Vojteková, M., Vrana, M., Čížová, K.: Collect. Czech. Chem. Commun., 2002; 67, 245-256.
Go to original source...
- Kopecký, F., Vojteková, M., Kaclík, P. et al.: J. Pharm. Pharmacol., 2004; 56, 581-587.
Go to original source...
Go to PubMed...